SEC Form 4 · accession 0001140361-16-046911
OncoMed Pharmaceuticals Inc · OMED
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Perry A Karsen
Director
Period of report
Jan 4, 2016
Accepted (ET)
Jan 6, 2016 · 5:21 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001302573
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $21.97 | Jan 4, 2016 | A | 30,189 | A | — | Jan 3, 2026 | Common Stock | 30,189 | 30,189 | D |
Explanation of responses
- F1The stock option will vest and become exercisable as to one-third of the shares subject thereto on each anniversary of the grant date, such that the option will be vested and exercisable for 100% of the shares subject thereto on January 4, 2019, subject to the Reporting Person's continued service to the Issuer through each such vesting date.